Abstract
Different pharmaceutical formulations of active pharmaceutical ingredient (API) of Rosuvastatin are analyzed qualitatively and quantitatively by using Raman spectroscopy. Raman spectroscopy represents a nondestructive, noninvasive, dependable, and swift analysis method utilized across a number of pharmaceutical drugs for quantification purposes. This study delves into the technique's capability in quantitatively analyzing pharmaceutical drugs. In this research, Raman spectroscopy was used to identify and quantify Raman spectral characteristics of rosuvastatin in solid dosage forms with various amounts of API and excipients. Variations in the Raman spectral data of all Rosuvastatin samples were examined. Quantification of rosuvastatin, an anti-hyperlipidemic drug, is essential due to its widespread use in treating patients with dyslipidemia to control bad cholesterol. Principal component analysis (PCA) and partial least squares regression analysis (PLSR) were used to check the quality and quantity of pharmaceutical drug. PLSR model, for this study, has been developed to predict varied drug concentrations in complex excipient matrices, to determine the root mean square error of calibration (RMSEC) and root mean square error of prediction (RMSEP), which were 0.95 mg and 1.71 mg, respectively, with a goodness of fit 0.99. The PLSR model, to estimate the amount of rosuvastatin concentrations in the unknown samples, was used. Raman spectroscopy along with PLSR and PCA proves to be a reliable approach for the assessment of rosuvastatin concentration in pharmaceutical dosage forms.